» Articles » PMID: 26551917

Morphometric Analysis of Explant Lungs in Cystic Fibrosis

Abstract

Rationale: After repeated cycles of lung infection and inflammation, patients with cystic fibrosis (CF) evolve to respiratory insufficiency. Although histology and imaging have provided descriptive information, a thorough morphometric analysis of end-stage CF lung disease is lacking.

Objectives: To quantify the involvement of small and large airways in end-stage CF.

Methods: Multidetector computed tomography (MDCT) and micro-CT were applied to 11 air-inflated CF explanted lungs and 7 control lungs to measure, count, and describe the airway and parenchymal abnormalities in end-stage CF lungs. Selected abnormalities were further investigated with thin section histology.

Measurements And Main Results: On MDCT, CF explanted lungs showed an increased median (interquartile range) number (631 [511-710] vs. 344 [277-349]; P = 0.003) and size of visible airways (cumulative airway diameter 217 cm [209-250] vs. 91 cm [80-105]; P < 0.001) compared with controls. Airway obstruction was seen, starting from generation 6 and increasing to 40 to 50% of airways from generation 9 onward. Micro-CT showed that the total number of terminal bronchioles was decreased (2.9/ml [2.6-4.4] vs. 5.3/ml [4.8-5.7]; P < 0.001); 49% were obstructed, and the cross-sectional area of the open terminal bronchioles was reduced (0.093 mm(2) [0.084-0.123] vs. 0.179 mm(2) [0.140-0.196]; P < 0.001). On micro-CT, 41% of the obstructed airways reopened more distally. This remodeling was confirmed on histological analysis. Parenchymal changes were also seen, mostly in a patchy and peribronchiolar distribution.

Conclusions: Extensive changes of dilatation and obstruction in nearly all airway generations were observed in end-stage CF lung disease.

Citing Articles

Rescue of Mutant CFTR Channel Activity by Investigational Co-Potentiator Therapy.

Bacalhau M, Ferreira F, Azevedo M, Rosa T, Buarque C, Lopes-Pacheco M Biomedicines. 2025; 13(1).

PMID: 39857666 PMC: 11762957. DOI: 10.3390/biomedicines13010082.


Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Dacco V, Gramegna A, Rosazza C, Mariani A, Biffi A, Lanfranchi C Lung. 2024; 203(1):9.

PMID: 39614886 DOI: 10.1007/s00408-024-00768-1.


Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels.

OBrien C, Spencer S, Jafari N, Huang A, Scott A, Cheng Z ACS Biomater Sci Eng. 2024; 10(10):6558-6568.

PMID: 39297972 PMC: 11483100. DOI: 10.1021/acsbiomaterials.4c01271.


Considerations for the use of inhaled antibiotics for in people with cystic fibrosis receiving CFTR modulator therapy.

Burgel P, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz J BMJ Open Respir Res. 2024; 11(1).

PMID: 38702073 PMC: 11086488. DOI: 10.1136/bmjresp-2023-002049.


Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis.

Bacalhau M, Camargo M, Lopes-Pacheco M J Pers Med. 2024; 14(1).

PMID: 38248793 PMC: 10820563. DOI: 10.3390/jpm14010093.